Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 200 Jobs Expected to Be Cut at Banyu by End of March
March 27, 2006
- Blopress Reduces Onset of Hypertension by 15.6%: Takeda
March 27, 2006
- SSP Extends Childcare-leave Period to 3 Years
March 27, 2006
- Crestor Reverses Plaque Build-up in Coronary Artery Disease
March 27, 2006
- HUMAN RESOURCES NEWS IN BRIEF
March 27, 2006
- Baraclude More Beneficial than Lamivudine for CHB
March 27, 2006
- Taisho to Increase Focus on Health & Beauty Business
March 27, 2006
- Sales Up 9.7% in 2005 Targeting Diabetes: Novo Nordisk
March 27, 2006
- US Study Shows Good Results for NM-702 Against ASO
March 27, 2006
- SELF-MEDICATION NEWS IN BRIEF
March 27, 2006
- Takeda Announces License Agreement for Tavocept in Japan
March 27, 2006
- 3 Bioventures to Jointly Develop Anticancer Agents
March 27, 2006
- MEDICAL DEVICE NEWS IN BRIEF
March 27, 2006
- NPhA Criticizes Takeda's Attitude toward Chain Pharmacies
March 27, 2006
- Korosho Submits Proposed GL for Animal Studies
March 27, 2006
- Hokuyaku, Takeyama to Integrate Management
March 27, 2006
- R&D NEWS IN BRIEF
March 27, 2006
- BUSINESS NEWS IN BRIEF
March 27, 2006
- JPMA Health Policy Seminar
March 27, 2006
- Korosho Calls For Stable, Nationwide Supply of Generics at All Strengths
March 27, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…